Imed19-Privat
- Address
- lock Available on a paid plan
Cardiovascular and Metabolic Research
At Imed19-Privat in Vienna, clinical research focuses on cardiovascular diseases, nutritional and metabolic diseases, and metabolism. The studies are centered on major conditions such as atherosclerotic cardiovascular disease, calcific aortic valve stenosis, and elevated Lp(a), with an emphasis on testing new approaches to reduce heart-related risk and slow disease progression.
- Studies in cardiovascular disease are evaluating whether new treatments can lower the risk of major heart events and improve long-term outcomes.
- Research in metabolic disease includes efforts to support weight reduction and better control of type 2 diabetes.
- Kidney-related research is also included, particularly for people with chronic kidney disease and albuminuria.
Overall, the site is exploring therapies that aim to improve heart, kidney, and metabolic health in patients with overlapping chronic conditions.
Kidney and Cardiometabolic Care Studies
Clinical trials at Imed19 Privat also address the connection between chronic kidney disease, diabetes mellitus type 2, and broader cardiometabolic risk. These studies are designed to test whether new treatment combinations can improve kidney protection while also reducing cardiovascular complications.
- Research is examining therapies for albuminuria and kidney decline in people with chronic kidney disease.
- Several trials focus on people with type 2 diabetes who also have elevated cardiovascular risk.
- The goal is to find better ways to prevent hospitalization, worsening kidney function, and heart-related events.
This makes the site a relevant center for studies linking kidney health with broader metabolic and cardiovascular outcomes.
Obesity and Lipid-Related Research
The site is involved in studies of obesity, overweight, and abnormal lipid-related risk, including elevated lipoprotein(a). These trials are exploring whether new therapies can support weight loss, improve metabolic health, and reduce the chance of serious cardiovascular events.
- Trials in obesity and overweight are assessing support for healthier body weight and better diabetes control.
- Lipid-focused research is looking at ways to lower Lp(a) and reduce heart disease risk.
- The research aims to improve prevention for people with combined metabolic and cardiovascular risk factors.
Together, these studies reflect a strong interest in prevention-oriented care for patients with weight, lipid, and heart-related conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novartis Pharma AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Imed19-Privat
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Oct 2021 | Jan 2025 |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.